The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held with great fanfare in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for patients with blood diseases and hematological malignancies. At this year’s conference, a study by the team of Professor Ruijuan Sun from Hebei Yanda Lu Daopei Hospital in China was included for poster presentation. The study revealed that using CD7-CAR-T cell therapy as a bridge to stem cell transplantation showed similar efficacy and safety in treating pediatric acute T-cell lymphoblastic leukemia compared to those who received chemotherapy and then underwent transplantation. This publication has the privilege of inviting Professor Ruijuan Sun to share the research findings and their clinical implications with peers immediately.

From April 14 to 17, 2024, the 50th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) was grandly held in Glasgow, UK. This year marks the 50th anniversary of EBMT, and the event brought together leaders in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. Together, they reviewed the remarkable achievements in the field of blood and marrow transplantation over the past 50 years and explored future prospects for patient management. At the conference, our magazine's onsite reporters specially invited Professor Jun Ma, a leading figure in hematology from the Harbin Institute of Hematological Oncology, to recount the history of hematopoietic stem cell transplantation and share his profound insights from attending the EBMT conferences for over four decades.

On March 30, 2024, the inaugural academic forum of the Ocular Lymphoma Collaboration Group was successfully held in Beijing, hosted by Peking University Health Science Center affiliated Beijing Tongren Hospital, the China Health Science and Technology Promotion Association, Beijing Public Health Science Popularization Association, and the Beijing Chen Jumei Public Welfare Foundation. The event, organized by the Cell Immunotherapy Professional Committee of the China Health Science and Technology Promotion Association, saw active exchanges and lively discussions among renowned domestic and international experts and scholars on the latest developments and hot topics in the diagnosis and treatment of ocular lymphoma. Professor Jianmin Ma, the head of the collaboration group and chairman of the conference from Peking University Health Science Center affiliated Beijing Tongren Hospital, was interviewed by "Oncology Frontier - Hematology Frontier" where he shared insights into the establishment of the Ocular Lymphoma Collaboration Group, research progress on ocular adnexal lymphoma, and treatment strategies.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a primary treatment for malignant blood diseases, with its numbers increasing annually. China is a region with moderate prevalence of hepatitis B virus (HBV), with approximately 5% to 6% of the population carrying hepatitis B surface antigen (HBsAg), and an annual incidence rate of about 1%. Patients positive for HBsAg or with past HBV infection are at risk of HBV reactivation during immunosuppressive therapy, chemotherapy, or monoclonal antibody-targeted therapy, with a higher risk during allo-HSCT. However, there is currently a lack of standardized clinical consensus or guidelines for the prevention and treatment of HBV reactivation after allo-HSCT in China. To address this, the Hematopoietic Stem Cell Application Group of the Hematology Branch of the Chinese Medical Association formulated and released the "Chinese Expert Consensus on Prevention and Treatment of Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (2023 Edition)." At the recently concluded 13th National Congress of Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, Professor Yi Luo from the , as the principal expert of the consensus, provided an interpretation of the consensus, aiming to provide clinical guidance for hematologists, hematopoietic stem cell transplantation sub-specialists, and related physicians.

The European Society for Blood and Marrow Transplantation (EBMT) annual meeting is one of the most influential international academic conferences in the field of hematology. The 50th EBMT annual meeting (EBMT 2024) was held from April 14 to April 17 in Glasgow, UK, bringing together nearly 6,000 experts and scholars from around the world to discuss the latest research on hematopoietic stem cell transplantation and cell therapy. In this issue, "Oncology Frontier - Hematology Frontier" has specially invited Director Pan Jing from Beijing Gaobo Hospital to comment on two studies in the field of acute lymphoblastic leukemia (ALL).

From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in the renowned city of Glasgow, United Kingdom. This year marks the 50th anniversary of EBMT's establishment, and the conference brought together leading figures in the field of hematopoietic stem cell transplantation, along with over 6,000 hematologists and experts from around the globe. Together, they reviewed the remarkable achievements made in the field of blood and marrow transplantation over the past 50 years and explored future prospects for patient management.